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~ Prooxldatlve Effects of Nitroglycerin In 
Hyperllpldernlc Animals: Oxidative Stress In 
Vasculature as an Initiating Event Leading to 
Impaired Endothelial Relaxation and Increased 
Plasma Oxidation 
T, Heltzer, A, Kontush, R, Macharzlna, T, M011er-Bertroaro, D Lava,, 
B, Freeman, U. Belslogel, 1", Melneaz, 1", M(Jnzel, University Hospital 
Eppondorf, OIv, of Cardiology, Hamburg, Germany 
Ba~ground: Eltrly stages of etherosclerosls have been shown to be ease. 
elated with endothelial dysfunction secondary to decreased endothelial nitric 
oxide (=NO) btoactlvity following reaction with endothelial superoxldo (=O~), 
In vitro experiments demonstrated potent antlatheroselerotlc effects of .NO 
suggesting that treatment with .NO (e,g, via organic nitrates) could compen. 
eats for the dlmlnlshad availability of endothelial =NO, Nitric oxide, however, 
may also react with endothelial.derived tO~ In order to form the potent 
oxld,nt and inhibitor of vascular function pemxynltrlto (ONOO), 
Methods and Results: W~' treated Watnnobe rabbits (heritable model of 
hypefllptdemts) for a 3 d period with nitroglycerin (NTG) pntohe~, I~ndothetlsl 
function was determined using the ondothollum dependant vesodllator acetyl- 
choline (ACh) In isometric tension studies, Relative rotes of vascular ,0~ 
prediction were determined using the luolgenln assay, We also tested the In. 
ltuonoe of In vlvo NTG treatment on oxidative stress, as Indicated by IipophlUc 
and hydropl~lllc anttoxld,~nt depletion In plasma and plasma oxldlzabillty, In 
In(net ve~s(jIs of hyperllptdemlc anlmals, .0~ production 2. fold increased 
ne tempt(rod to controls and NADH.oxlda.qe activity was significantly greater 
than can(role, NTG treatment of hyperllpldsmle (~nlmals decreased the lu- 
clgenln signal but Increased NADH.Oxldose activity suggesting tnoroasod 
vascular pemxynltrlto formation, NTG treatment also decreased plasma lev. 
sis of rt and II.caroteno while having no significant effects on hydrophllic 
~ntloxldsnt levels, In vitro, NTG.exposuro reduced plasma oxlcllzabllity while 
Increasing It following in vlvo treatment, 
Conch+siena: These observations suggest that short-term treatment of 
hyperltpldemlc animals with NTG worsens rather than improves endothelial 
dysfunction, The Increase in plasma oxldiznblllty and decrease in llpophtlie 
anttoxldant levels reflects increased oxidative stress within the vaseulaturo, 
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~ Laek of Efficacy of Intravenous Basic Flbroblast 
Growth Fa:tor In Promoting Myocardial 
Anglogeneels 
V ThirumurtL M. Shou, E. Hedge, L, Goncalves, S.E. Epstein, 
D.F, Lazarous, E.F. Unger. Cardiology Branch NHLBI, Bethesda MD, USA 
Back.qmund: Basic ~'ibmblast growth factor (bFGF) is in clinical teals as an 
angiogonic agent in ischemic cardiovascular disease; however, its optimal 
route of administration is unknown. We have shown that bFGF promotes 
coronary collateral expansion when administered by a systemic arterial mute 
(left atrium) or by direct Intracoronary injection. The Intravenous (IV) mute 
has obvious p~aetleal advantages over arterial routes; however, it has not 
boon carefully evaluated in the context of myocardial angiogenesis. Using a 
bFGF dose and schedule that were previously found to be effective following 
systemic arterial administration, we tested repetitive IV bFGF infusion as a 
means to promote myocardial collateral development in our established dog 
model. 
Methods: Mongrel dogs undawvenl placement of amemid constrictors on 
the left circumflex coronary artery. Animals were randomized to receive bFGF 
100 .g/kg daily (n = 7) or placebo (n = 9) as a 3-4 hour IV infusion, days 10 
through 16 after instrumentation. 
Resuffs: Collateral pedusion, assessed with fluorescent micmspheres 
during maximal chromonar-indueed vasodilation, was equivalent in both 
groups at all time points (10, 17, 24, 31 and 38 days after ameroid placement). 
Conclusions: IV bFGF was ineffective in myocardial angiogenesis likely 
because 0t first pass lung uptake by low affinity receptors, These findings 
raise concerns regarding use of IV bFGF administration for myocardial an- 
giogenesis in future clinical trials. 
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~ Ab¢lxlmab Reduces Urgent Target Vessel 
Revas©ularlzatlon st 30 Days After Primary 
Angloplaety, Independently of Acute Anglographlc 
Results, The RAPPORT Trial 
S,J, Broner, L,A, Barr, E,D, Cohen, H,J, White, O,J, Molltemo, H,B, Ch~k, 
M,B, Eflron, E,J, Topoi, For the RAPPORT Investigators, Clove/anti Clinic, 
Cleveland, Ohio, USA 
Background: Roourront tschoml~ lending to urgent mvasculafi~atlon imme. 
dtately alter primary angloplssty is eaused by abrupt vessel closure, related 
to residual thrombosis, obstructing dissections, or less than optimal coronary 
flow, Abcixlmab reduces isoho~'!: eomplications of PTCA, but was not tested 
in primary angloplasty, 
Mefhnds: Pts with nellie MI < 12 hr, were rnndomized to placebo tP, rl = 
242) or aboiximab (A, n m 241) as an adjunct to primary angioplasty, Death, 
reinfaretion and recurrent ischemia le~dlng to ~rgent target vessel rovas- 
euladzatlon (TVR) at 7 and 30 days, and angiograms were independently 
analyzed centrally, 
Results: Outcomes at 30 days among pts receiving study drug (89% of 
those enrolled): 
P (n = 213) A (= 216) p value 
Post PTCA stonosis 37% [16,48] 38% [2B,46] 059 
Post PTCA TIMI Ill 05% 87'% 053 
Composite 1Q3% 49% 003 
Do.~th t 9% I 8% 093 
Roinl~rction 4,7% ~7% 028 
TVR 5,6% 18% o 03 
Conclusion: As compared with placebo, abc(ximab markedly reduces 
need for urgent TVR at 30 days. This occurred despite similar acute an- 
giogmphtc results and highlights the contribution of vessel wall passivation 
provided by abciximab to the prevention of recurrent isehemic events. 
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~2"-~ Complementar i ty  of  Stent ing and Abclximab for  
Percutaneous Coronary  In tervent ion  
D,J. Kereiakos, A.M. Lincoff, M.L Simoons, M.J. deBoer, J.E. Tcheng, 
A, Vahanian, K.M. Anderson, H.F. Weisman, R.A. Calift, E.J. Topoi. The 
Lindner Center, Cincinnale, Ohio, USA 
The role of abciximab (At platelet GP Ub/llla blockade in patients (pts) with 
coronary stent placement has not been determined, Stents (St were placed 
in 529 patients in the combined EPIC (n = 7), EPILOG (n = 382) and 
CAPTURE (n = 140) placebo (P) controlled randomized trials of A therapy. 
S were provisional or planned (EPILOG stent subsludy) in 473 and 56 pts 
respectively, Clinical events for Pts randomized to A (n = 308) or P (n = 221), 
hazard ratio (HR) and 95% confidence intervals (CI) are shown. Sun~ival was 
enhanced and the occurrences of death/MI, death/MI/Urg Int or TVR were 
reduced in A treated pts. 
Event % 30 Day 6 Month 
P A HR CI P A HR CI 
Death 1.4 0 23 1.0 039 (009, 1.64) 
Death/MI 16.6 6.5 0.32 (019.0 56) 20.4 85 0.38 (0.24.0.62) 
Doath/MI/Urg Int 20 8 8.1 0.36 t0.22.055) 22.6 11.1 0.46 (0.28, 0.77) 
DeathtMI/TVR 20.8 10.1 0.44 (0.28, 0.70) 300 22.4 0.67 (0.45. 0.96i 
Urg tnt 7.7 2.0 0.23 (009,0.59) 8.9 25 0.27 (0 10. O 7~) 
TVR 8.6 3.9 041 (020, 0.85) 19 4 146 070 (0.46, 1 07) 
('P = 0.04; TVR = target vessel revaseularization; URG INT = Urgent Intervention) 
These r"mdomized trie]s demonstrate prophylactic A improves outcomes 
in pts following provisional-unplanned coronary stent placement. Extrapo- 
lation of these findings to elective stenting requires study in on ongoing 
dedicated trial. 
